TITLE

The Indolent Natural History of Essential Thrombocythemia: A Challenge to New Drug Development

AUTHOR(S)
Tefferi, Ayalew
PUB. DATE
January 2005
SOURCE
Mayo Clinic Proceedings;Jan2005, Vol. 80 Issue 1, p97
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on essential thrombocythemia (ET). This disease was first described in 1934, and subsequently classified as a myeloproliferative disorder in 1951. Evidence-based management currently dictates the use of hydroxyurea in high-risk patients, while drug therapy has not been shown, in a controlled setting, to have an advantage over observation alone in either low-risk or indeterminate-risk patients. The article further discusses the impetus to use drugs other than hydroxyurea in patients with ET and how can one best determine their efficacy.
ACCESSION #
15661493

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics